In short
Patritumab Deruxtecan (HER3-DXd) is an innovative antibody-drug conjugate being studied in clinical trials for treating several types of cancer, including breast cancer, lung cancer, colorectal cancer, and solid tumors. This article explores the ongoing research into this promising new therapy, its potential benefits, and what patients should know about participating in clinical trials.
At a glance
- Drug Name
- Patritumab Deruxtecan (HER3-DXd, U3-1402)
- Drug Type
- Antibody-drug conjugate targeting HER3
- Cancer Types Studied
- Breast cancer, Non-small cell lung cancer, Colorectal cancer, Solid tumors
- Administration
- Intravenous infusion, typically every 3 weeks
- Common Dosage
- 5.6 mg/kg (may vary by trial)
- Key Outcomes Measured
- Objective response rate, Duration of response, Progression-free survival
- Safety Monitoring
- Adverse events, Lab abnormalities, Special focus on interstitial lung disease
- Combination Studies
- With chemotherapy, endocrine therapy, and targeted therapies like olaparib
- Biomarker Analysis
- HER3 expression levels, ERBB3 mRNA expression
- Quality of Life Assessments
- Using EORTC QLQ-BR45 and QLQ-C30 questionnaires
What is Patritumab Deruxtecan?
Patritumab Deruxtecan is an innovative cancer treatment that belongs to a class of drugs called antibody-drug conjugates (ADCs). It's also known by other names such as HER3-DXd and U3-1402. This medication combines two important components:
- An antibody that targets a specific protein on cancer cells called HER3 (human epidermal growth factor receptor 3)
- A powerful anti-cancer drug (deruxtecan) that's attached to the antibody
This unique combination allows the drug to deliver its cancer-fighting payload directly to tumor cells, potentially increasing its effectiveness while reducing side effects on healthy cells.
How Does It Work?
Patritumab Deruxtecan works in a targeted manner:
- The antibody part of the drug seeks out and attaches to HER3 proteins on the surface of cancer cells.
- Once attached, the cancer cell absorbs the entire drug complex.
- Inside the cancer cell, the anti-cancer drug (deruxtecan) is released.
- The released drug damages the DNA of the cancer cell, leading to its death.
This mechanism allows for a more precise attack on cancer cells while potentially sparing healthy cells, which may lead to fewer side effects compared to traditional chemotherapy.
What Cancers Does It Treat?
Patritumab Deruxtecan is being studied for several types of cancer, including:
- Breast Cancer: Particularly in patients with HER3-positive metastatic breast cancer (cancer that has spread to other parts of the body).
- Non-Small Cell Lung Cancer (NSCLC): Especially in patients whose cancer has specific mutations in the EGFR gene and has progressed after other treatments.
- Colorectal Cancer: In patients with advanced or metastatic colorectal cancer who have received at least two prior lines of therapy.
- Other Solid Tumors: Research is ongoing to explore its effectiveness in various other types of solid tumors.
Clinical Trials and Research
Patritumab Deruxtecan is currently being studied in several clinical trials to evaluate its safety and effectiveness. Some key studies include:
- HERTHENA-Lung01: A phase 2 study in patients with previously treated metastatic or locally advanced EGFR-mutated NSCLC.
- HERTHENA-Lung02: A phase 3 study comparing Patritumab Deruxtecan to standard chemotherapy in patients with EGFR-mutated NSCLC that has progressed after other treatments.
- A phase 1/2 study in patients with HER3-positive metastatic breast cancer.
- A phase 2 study in patients with advanced or metastatic colorectal cancer.
These trials aim to determine how well the drug works, what doses are most effective, and what side effects may occur.
Administration and Dosage
Patritumab Deruxtecan is typically administered as an intravenous (IV) infusion. The most common dosage being studied is 5.6 mg/kg given every 3 weeks. However, some studies are exploring different dosing regimens, including:
- Fixed dosing at 5.6 mg/kg every 3 weeks
- Up-titration dosing, starting at a lower dose and gradually increasing
The exact dosage and schedule may vary depending on the type of cancer being treated and individual patient factors. Always follow your doctor's instructions regarding dosage and administration.
Potential Side Effects
Like all medications, Patritumab Deruxtecan can cause side effects. Some of the potential side effects reported in clinical trials include:
- Diarrhea
- Nausea and vomiting
- Fatigue
- Decreased appetite
- Low blood cell counts
- Interstitial lung disease (a rare but serious lung condition)
It's important to note that not everyone experiences these side effects, and your healthcare team will monitor you closely during treatment. Always report any new or worsening symptoms to your doctor.
Future Prospects
Patritumab Deruxtecan shows promise in treating various types of cancer, particularly in patients who have progressed on other treatments. Ongoing research is exploring its potential in different cancer types and treatment combinations. For example:
- Its use in combination with other cancer drugs, such as olaparib in breast cancer.
- Its effectiveness in treating brain metastases (cancer that has spread to the brain).
- Its potential as a neoadjuvant treatment (given before surgery) in breast cancer.
As research continues, we may learn more about how to use this drug most effectively and in which patients it works best. If you're interested in learning more about Patritumab Deruxtecan or participating in a clinical trial, talk to your oncologist about whether this treatment might be appropriate for you.